Cargando…
Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance
Neuroblastoma (NB) is a pediatric tumor of neural crest origin with heterogeneous phenotypes. While low stage tumors carry a favorable prognosis, over 50% of high risk NB relapses after treatment with a fatal outcome. Thus, developing therapies targeting refractory NB remains an unsolved clinical pr...
Autores principales: | Czarnecka, Magdalena, Trinh, Emily, Lu, Congyi, Kuan-Celarier, Anna, Galli, Susana, Hong, Sung-Hyeok, Tilan, Jason U., Talisman, Nicholas, Izycka-Swieszewska, Ewa, Tsuei, Jessica, Yang, Chao, Martin, Samantha, Horton, Meredith, Christian, David, Everhart, Lindsay, Maheswaran, Induja, Kitlinska, Joanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333135/ https://www.ncbi.nlm.nih.gov/pubmed/25132261 http://dx.doi.org/10.1038/onc.2014.253 |
Ejemplares similares
-
Neuropeptide Y and its Y2 Receptor – Potential Targets in Neuroblastoma Therapy
por: Lu, Congyi, et al.
Publicado: (2010) -
Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects
por: Tilan, Jason U., et al.
Publicado: (2013) -
High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases
por: Hong, Sung-Hyeok, et al.
Publicado: (2015) -
Neuropeptide Y and its receptors in prostate cancer: associations with cancer invasiveness and perineural spread
por: Sigorski, Dawid, et al.
Publicado: (2022) -
Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma
por: Lu, Congyi, et al.
Publicado: (2022)